Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

CHMP Recommends Frontline Approval for Ibrutinib in CLL

April 29th 2016

The Committee for Medicinal Products for Human Use has recommended the frontline approval for ibrutinib (Imbruvica) as a single-agent for patients with chronic lymphocytic leukemia.

Acalabrutinib Challenges Ibrutinib in High-Risk CLL Trial

April 22nd 2016

Patients with relapsed chronic lymphocytic leukemia face a difficult treatment journey, but a phase III safety and efficacy trial involving the second-generation Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) will help inform oncologists about whether the emerging agent can offer a greater benefit to patients with high-risk disease over ibrutinib (Imbruvica).

FDA Approves Venetoclax for CLL

April 11th 2016

The FDA approved the BCL-2 inhibitor venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) who have a 17p deletion (del[17p]), following at least 1 prior therapy.

Dr. Jeffrey Jones on NCCN Recommendations for Relapsed Patients With CLL

April 4th 2016

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses NCCN recommendations for treatment of relapsed patients with chronic lymphocytic leukemia (CLL).

Optimizing Current Treatments for CLL as New Agents Are Investigated

April 2nd 2016

Jeffrey Jones, MD, updated attendees at the 2016 NCCN Annual Conference on the latest developments in chronic lymphocytic leukemia.

Byrd Says Frontline Ibrutinib Approval Moves CLL Closer to a Cure

March 24th 2016

John Byrd, MD, explains why he believes the ibrutinib approval is practice changing, and how he thinks the agent should be utilized next.

Dr. Stilgenbauer on Activity With Venetoclax in Patients With CLL

March 22nd 2016

Stephen Stilgenbauer, MD, associate professor, Department of Haematology, Oncology, Rheumatology and Infectious Diseases, University of Ulm, Germany, discusses the clinical activity seen with venetoclax in patients with chronic lymphocytic leukemia, according to results of the open-label, single-arm, multicenter M13-982 study.

Dr. Byrd on Ibrutinib's Impact on Treatment Landscape in CLL

March 21st 2016

John Byrd, MD, director of the Division of Hematology, Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, discusses the RESONATE 2 study, which looked at ibrutinib versus chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia (CLL).

Newer Agents, Combinations Being Studied for Targeted Therapies in CLL

March 20th 2016

Targeted agents, particularly ibrutinib and idelalisib, are becoming increasingly important in the treatment of chronic lymphocytic leukemia, and have replaced chemotherapy in many settings.

Dr. Susan O'Brien on Next-Generation Small Molecules in CLL

March 20th 2016

Susan O’Brien, MD, Associate Director for Clinical Science for the Chao Family Comprehensive Cancer Center and Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses upcoming agents in chronic lymphocytic leukemia (CLL).

Extended Phase III Data Illuminates Ibrutinib Survival Benefit in CLL

March 20th 2016

Extended follow-up data continue to demonstrate the efficacy and tolerability of ibrutinib in previously treated patients with chronic lymphocytic leukemia, including those with high-risk gene mutations and prognostic features.

Dr. Jennifer Brown on RESONATE 2 Trial in CLL

March 19th 2016

Jennifer Brown MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses RESONATE 2 and frontline ibrutinib use in patients with chronic lymphocytic leukemia (CLL).

Novel BTK, PI3K Inhibitors on Horizon for Relapsed CLL

March 19th 2016

A multitude of PI3K and BTK inhibitors are currently in development that offer distinct advantages over existing treatments for patients with relapsed chronic lymphocytic leukemia.

Frontline Ibrutinib Highly Effective Across Subgroups for Elderly Patients With CLL/SLL

March 18th 2016

Frontline treatment with ibrutinib reduced the risk of progression or death by 84% compared with single-agent chlorambucil for elderly patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

New Agents Transform Treatment of Non-Hodgkin Lymphoma

March 16th 2016

Mitchell Smith, MD, discusses advancements in the field of non-Hodgkin lymphoma.

Expanded Indication Sought for Ofatumumab in CLL

March 15th 2016

A supplemental new drug application has been submitted to the FDA for ofatumumab in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia.

FDA Approves Ibrutinib for Frontline CLL

March 4th 2016

The FDA has approved ibrutinib (Imbruvica) for the frontline treatment of chronic lymphocytic leukemia based on data from the RESONATE-2 trial.

Kipps on Impact of Potential Venetoclax Approval and Other Novel CLL Agents

February 25th 2016

Thomas Kipps, MD, PhD, provides insight on the potential impact of an FDA approval for venetoclax, the management of tumor lysis syndrome associated with venetoclax, and combination possibilities for the agent.

Upcoming Approvals, Combinations Will Transform CLL Treatment

February 25th 2016

Victor Y. Yazbeck, MD, discusses the potential for venetoclax and idelalisib, both as single agents and in combination with other agents, and what questions remain regarding both therapies in CLL.

Expert Discusses Role of Venetoclax and Future of CLL Care

February 25th 2016

Jeffrey Jones, MD, discusses exciting data with venetoclax, the role it is likely to have in the treatment paradigm of CLL, and what role it may have alongside ibrutinib and idelalisib.

NEXT PAGE
PREVIOUS PAGE